These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

593 related articles for article (PubMed ID: 24607323)

  • 1. Sex differences in Parkinson's disease.
    Gillies GE; Pienaar IS; Vohra S; Qamhawi Z
    Front Neuroendocrinol; 2014 Aug; 35(3):370-84. PubMed ID: 24607323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Independent influences of sex steroids of systemic and central origin in a rat model of Parkinson's disease: A contribution to sex-specific neuroprotection by estrogens.
    Gillies GE; McArthur S
    Horm Behav; 2010 Jan; 57(1):23-34. PubMed ID: 19538962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral vs. Central Sex Steroid Hormones in Experimental Parkinson's Disease.
    McArthur S; Gillies GE
    Front Endocrinol (Lausanne); 2011; 2():82. PubMed ID: 22649388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex differences in Parkinson's disease: Features on clinical symptoms, treatment outcome, sexual hormones and genetics.
    Jurado-Coronel JC; Cabezas R; Ávila Rodríguez MF; Echeverria V; García-Segura LM; Barreto GE
    Front Neuroendocrinol; 2018 Jul; 50():18-30. PubMed ID: 28974386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose- and sex-dependent effects of the neurotoxin 6-hydroxydopamine on the nigrostriatal dopaminergic pathway of adult rats: differential actions of estrogen in males and females.
    Murray HE; Pillai AV; McArthur SR; Razvi N; Datla KP; Dexter DT; Gillies GE
    Neuroscience; 2003; 116(1):213-22. PubMed ID: 12535954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex-specific neuroprotection by inhibition of the Y-chromosome gene,
    Lee J; Pinares-Garcia P; Loke H; Ham S; Vilain E; Harley VR
    Proc Natl Acad Sci U S A; 2019 Aug; 116(33):16577-16582. PubMed ID: 31371505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Potential of L-Type Calcium Channels as a Drug Target for Neuroprotective Therapy in Parkinson's Disease.
    Liss B; Striessnig J
    Annu Rev Pharmacol Toxicol; 2019 Jan; 59():263-289. PubMed ID: 30625283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developmental and genetic influences upon gender differences in methamphetamine-induced nigrostriatal dopaminergic neurotoxicity.
    Dluzen DE; McDermott JL
    Ann N Y Acad Sci; 2004 Oct; 1025():205-20. PubMed ID: 15542719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurotrophic factors hold promise for the future of Parkinson's disease treatment: is there a light at the end of the tunnel?
    Nasrolahi A; Mahmoudi J; Akbarzadeh A; Karimipour M; Sadigh-Eteghad S; Salehi R; Farhoudi M
    Rev Neurosci; 2018 Jul; 29(5):475-489. PubMed ID: 29305570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of estrogen in the treatment of Parkinson's disease.
    Tsang KL; Jiang H; Ramsden DB; Ho SL
    Parkinsonism Relat Disord; 2001 Oct; 8(2):133-7. PubMed ID: 11489678
    [No Abstract]   [Full Text] [Related]  

  • 11. Sex differences in Parkinson's disease and other movement disorders.
    Smith KM; Dahodwala N
    Exp Neurol; 2014 Sep; 259():44-56. PubMed ID: 24681088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Where do we stand on neuroprotection? Where do we go from here?
    Shoulson I
    Mov Disord; 1998; 13 Suppl 1():46-8. PubMed ID: 9613718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroactive steroids and Parkinson's disease: Review of human and animal studies.
    Bourque M; Morissette M; Di Paolo T
    Neurosci Biobehav Rev; 2024 Jan; 156():105479. PubMed ID: 38007170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Therapeutic Strategies and Perspectives for Neuroprotection in Parkinson's Disease.
    Ghanta MK; Elango P; L V K S B
    Curr Pharm Des; 2020; 26(37):4738-4746. PubMed ID: 32065086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sex dimorphisms in the neuroprotective effects of estrogen in an animal model of Parkinson's disease.
    Gillies GE; Murray HE; Dexter D; McArthur S
    Pharmacol Biochem Behav; 2004 Jul; 78(3):513-22. PubMed ID: 15251260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotective effect of silymarin in a MPTP mouse model of Parkinson's disease.
    Pérez-H J; Carrillo-S C; García E; Ruiz-Mar G; Pérez-Tamayo R; Chavarría A
    Toxicology; 2014 May; 319():38-43. PubMed ID: 24607817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nicotinic receptors as CNS targets for Parkinson's disease.
    Quik M; Bordia T; O'Leary K
    Biochem Pharmacol; 2007 Oct; 74(8):1224-34. PubMed ID: 17631864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotective therapies.
    Simon DK; Standaert DG
    Med Clin North Am; 1999 Mar; 83(2):509-23, viii. PubMed ID: 10093591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are dopamine receptor agonists neuroprotective in Parkinson's disease?
    Le WD; Jankovic J
    Drugs Aging; 2001; 18(6):389-96. PubMed ID: 11419913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes.
    Maruyama W; Akao Y; Carrillo MC; Kitani K; Youdium MB; Naoi M
    Neurotoxicol Teratol; 2002; 24(5):675-82. PubMed ID: 12200198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.